Technology
Revolutionary Cancer Drug Surv.m-CRA from Kagoshima University Enters Final Trials | First New Bone Tumor Drug in 30 Years
Kagoshima University's oncolytic virus "Surv.m-CRA-1" enters final clinical trials for primary malignant bone tumors. This revolutionary treatment can eliminate cancer stem cells resistant to conventional therapies, offering new hope for bone cancer patients who haven't seen a new drug in over 30 years. Learn about Japan's next-generation cancer therapy targeting 2027 approval.